The Russian government announced on Wednesday the start of the preparatory phase for clinical trials of a personalized vaccine against melanoma , one of the most aggressive types of skin cancer , within 45 days .

After a month and a half has passed, the selected volunteers will begin their immunization sessions , marking a milestone in the development of cutting-edge cancer therapies.

The research, led by three prestigious Russian scientific institutes , received authorization from the Ministry of Health to move forward with the production of the first doses. According to Alexander Ginzburg , director of the renowned Gamaleya National Research Center , medical teams have already formed groups of volunteer patients, who will undergo personalized treatments based on their genetic profiles .

Each volunteer was evaluated using genomic analysis to identify potential adverse effects and specific benefits based on their individual biology. “ In science, every mistake points us in the wrong direction, and every discovery brings us closer to the solution, ” said Guínzburg, emphasizing the importance of precision in these types of studies.

The vaccine, developed using a messenger RNA (mRNA) platform , represents a significant advance in the field of personalized cancer immunotherapy . Based on the molecular analysis of each tumor, a unique formula is generated that trains the immune system to recognize and attack cancer cells without affecting healthy tissue.

Nicaragua will be part of the vaccine clinical trials

The project has sparked international interest. Nicaraguan Co-President Rosario Murillo announced that her country has joined the initiative and confirmed that negotiations are underway to establish a nuclear medicine center in Managua , in collaboration with the Russian State Atomic Energy Corporation .

With this initiative, Russia consolidates its position as a leader in cancer vaccine research and production , investing in new therapeutic alternatives to combat melanoma and other highly fatal diseases.